 |
answer text |
<p>The Government continues to monitor vaccine efficacy amongst different clinical
groups, including studies such as OCTAVE, looking at COVID-19 in people with and without
cancer and SOAP, measuring vaccine efficacy in blood cancer patients.</p><p>We have
been working on finding treatments to reduce mortality, hospitalisations and disease
severity. Immunocompromised individuals are a priority cohort for the research treatments
such as monoclonal antibody therapies, antivirals, and repurposed compounds.</p><p>Although
the shielding advice was paused on 1 April, the clinically extremely vulnerable are
advised to continue to take extra precautions to keep themselves safe, particularly
when meeting with people from outside their household. All clinically extremely vulnerable
people will have been offered a COVID-19 vaccination and are strongly encouraged to
take up their second dose when it is offered.</p><p>If an individual has concerns
about the impacts of COVID-19 on their own health condition then they should speak
to their general practitioner or specialist clinician.</p>
|
|
